Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
Novartis's Phase 3 trial for cholesterol drug pelacarsen failed to reduce cardiovascular risks, causing shares of Novartis, Amgen, and Ionis to decline. The trial's failure highlights the risks of investing in drug development.
How this was made
The 30-second read
Why it matters
The failure underscores the challenges in developing Lp(a)-lowering therapies and may delay market entry, affecting revenue expectations.
Market read
The trial miss triggers a sector-wide pullback, presenting short opportunities in affected stocks.
What to watch
Novartis may have alternative pipelines that could offset the setback.
Background
Novartis's pelacarsen trial was a high-profile attempt to address elevated Lp(a) levels, a known cardiovascular risk factor.
Ticker impact
Novartis announced its Phase 3 trial of pelacarsen failed to reduce cardiovascular events, causing its stock to tumble.
Downward pressure on NVS price in the short term.
Phase 3 failure is material for a late-stage drug; investors typically sell on such news.
Amgen shares fell alongside Novartis as the biopharma sector reacted to the trial failure.
Modest downside as investors rotate out of biopharma.
Sector sentiment spillover can affect peers even without company-specific events.
Ionis shares dropped as part of the biopharma selloff triggered by Novartis's trial miss.
Potential short-term decline.
Investors may penalize related biotech stocks in a broad selloff.
Market effects
Biopharma sector faces heightened risk perception after a major Phase 3 failure.
European and US biotech markets may see broader sell pressure.
Potential ripple effects on global biotech ETFs and related indices.
Counterpoint
If the trial failure is isolated, peers may rebound quickly once the market digests the news.
Key entities
- CompanyNovartis
Swiss pharmaceutical giant reporting trial failure.
- CompanyAmgen
Biotech peer affected by sector selloff.
- CompanyIonis
Biotech peer affected by sector selloff.
